
Breztri FDA Approval: First Triple Therapy Inhaler for Asthma in patients 12 years and older
The U.S. Food and Drug Administration has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) for the maintenance treatment of asthma in adults and adolescents aged 12 and older. The approval, announced on April 28, 2026, makes Breztri the first single-inhaler triple therapy authorized for asthma in patients as young as 12 —










